Evaluation of the hemostatic effect of desmopressin nasal spray in rhinoplasty
Phase 3
Recruiting
- Conditions
- Rhinoplasty.
- Registration Number
- IRCT20210424051060N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
Age over 18 years
Hemoglobin above 10
Patients without coagulation disorders
Exclusion Criteria
Coagulant disorder
A condition associated with clot such as CVA, thrombosis
Drug sensitivity to desmopressin
Hypertension
Taking drugs that affect coagulation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bleeding. Timepoint: In the 30th and 60th minutes after the start of surgery. Method of measurement: According to Beozaart criteria.
- Secondary Outcome Measures
Name Time Method Surgeon satisfaction. Timepoint: At the end of surgery. Method of measurement: According to the Likert scale.;Length of surgery. Timepoint: End of surgery. Method of measurement: Surgery time based on minutes.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie desmopressin's hemostatic effect in rhinoplasty?
How does desmopressin nasal spray compare to standard-of-care hemostatic agents in rhinoplasty?
Are there specific biomarkers that predict response to desmopressin in post-rhinoplasty bleeding prevention?
What are the potential adverse events associated with desmopressin nasal spray in rhinoplasty patients?
What combination therapies or alternative drugs show promise for hemostasis in rhinoplasty compared to desmopressin?